Portfolio company
Caedo Oncology
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops monoclonal antibody therapeutics that induce programmed cell death in cancer cells for healthcare providers and patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Cadeo Oncology
The company develops monoclonal antibody-based immunotherapy treatments for cancer patients to induce programmed cell death in cancer cells.
Mersana Therapeutics
This company develops antibody-drug conjugates to treat various cancers for healthcare providers and patients within the oncology sector.
Callio Therapeutics
The company develops multi-payload antibody-drug conjugates to treat cancer patients.
CellmAbs
This biotech company develops monoclonal antibodies and adoptive cell therapies to treat oncology patients with solid tumours.
Mnemo Therapeutics
This biotechnology company develops cell therapies and an epigenetic antigen discovery platform to treat solid tumours and blood cancers for healthcare providers.
Sanavia Oncology
This company develops antibody drug candidates targeting cancer-specific epitopes in drug-resistant tumours for healthcare researchers and pharmaceutical partners.
Cellemedy
The company develops next-generation protein therapeutics and immuno-oncology drugs for patients suffering from cancer.
Alphina Therapeutics
This biotechnology company develops antibody-drug conjugates with novel payloads to treat solid tumours for healthcare providers and cancer patients.